Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer

Authors: Charu Aggarwal, Jeffrey C. Thompson, Austin L. Chien, Katie J. Quinn, Wei-Ting Hwang, Taylor A. Black, Stephanie S. Yee, Theresa E. Christensen, Michael J. LaRiviere, Benjamin A. Silva, Kimberly C. Banks, Rebecca J. Nagy, Elena Helman, Abigail T. Berman, Christine A. Ciunci, Aditi P. Singh, Jeffrey S. Wasser, Joshua M. Bauml, Corey J. Langer, Roger B. Cohen, Erica L. Carpenter

Published: 2020-02-26

DOI: 10.1158/1078-0432.ccr-19-3663

Source: Full article

Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Non–Small Cell Lung Cancer

Abstract